Cargando…
Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690807/ https://www.ncbi.nlm.nih.gov/pubmed/36430163 http://dx.doi.org/10.3390/ijms232213686 |
_version_ | 1784836885374304256 |
---|---|
author | Bergantim, Rui Peixoto da Silva, Sara Polónia, Bárbara Barbosa, Mélanie A. G. Albergaria, André Lima, Jorge Caires, Hugo R. Guimarães, José E. Vasconcelos, M. Helena |
author_facet | Bergantim, Rui Peixoto da Silva, Sara Polónia, Bárbara Barbosa, Mélanie A. G. Albergaria, André Lima, Jorge Caires, Hugo R. Guimarães, José E. Vasconcelos, M. Helena |
author_sort | Bergantim, Rui |
collection | PubMed |
description | Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD. |
format | Online Article Text |
id | pubmed-9690807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96908072022-11-25 Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept Bergantim, Rui Peixoto da Silva, Sara Polónia, Bárbara Barbosa, Mélanie A. G. Albergaria, André Lima, Jorge Caires, Hugo R. Guimarães, José E. Vasconcelos, M. Helena Int J Mol Sci Article Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD. MDPI 2022-11-08 /pmc/articles/PMC9690807/ /pubmed/36430163 http://dx.doi.org/10.3390/ijms232213686 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bergantim, Rui Peixoto da Silva, Sara Polónia, Bárbara Barbosa, Mélanie A. G. Albergaria, André Lima, Jorge Caires, Hugo R. Guimarães, José E. Vasconcelos, M. Helena Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title | Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title_full | Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title_fullStr | Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title_full_unstemmed | Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title_short | Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept |
title_sort | detection of measurable residual disease biomarkers in extracellular vesicles from liquid biopsies of multiple myeloma patients—a proof of concept |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690807/ https://www.ncbi.nlm.nih.gov/pubmed/36430163 http://dx.doi.org/10.3390/ijms232213686 |
work_keys_str_mv | AT bergantimrui detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT peixotodasilvasara detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT poloniabarbara detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT barbosamelanieag detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT albergariaandre detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT limajorge detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT caireshugor detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT guimaraesjosee detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept AT vasconcelosmhelena detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept |